Previous 10 | Next 10 |
home / stock / alpmy / alpmy news
Aravive's Reverse Merger Path to Public Company Creates Potentially Compelling Overlooked and Underfollowed Investment Opportunity If a company chooses to go public through a reverse merger instead of the more conventional IPO path, it has a higher chance to become an Overlooked and Underf...
A Phase 3 clinical trial, HIMALAYAS , evaluating FibroGen's ( FGEN -6% ) roxadustat in chronic kidney disease (CKD) patients who recently initiated dialysis met both primary endpoints . The data were presented at the American Society of Nephrology Kidney Week in Washington, DC. More ne...
TOKYO , Oct. 31, 2019 /PRNewswire/ -- The New England Journal of Medicine published detailed results from the Phase 3 ADMIRAL trial, which found that Astellas Pharma Inc.'s (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") XOSPATA ® (gilteritinib) demonstrated ...
TOKYO , Oct. 28, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of ASP1128 for patients at increased risk ...
The European Commission approves Astellas Pharma's ( OTCPK:ALPMY ) XOSPATA (gilteritinib) for the treatment of adult patients with relapsed/refractory FLT3 mutation-positive acute myeloid leukemia (AML), a type of AML with a poor prognosis. More news on: Astellas Pharma Inc., Astellas Ph...
TOKYO , Oct. 25, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") announced today that the European Commission (EC) has approved the oral once-daily therapy XOSPATA ™ (gilteritinib) as a monotherapy for the tre...
Shares of FibroGen ( FGEN ) have risen by 80% since I called the stock a Strong Buy back in 2016, noting that lead program roxadustat (a hypoxia-inducible factor-prolyl hydroxylase or HIF-PH inhibitor) offers several benefits over conventional injectable anemia treatments, including reductio...
TOKYO , Oct. 1, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced it will invest nearly $13 million into two innovation incubators operated by LabCentral, a premier United States -based laboratory fac...
Seattle Genetics ( SGEN +10.2% ) breaks out to an all-time high after the company and partner Astellas Pharma ( OTCPK:ALPMY ) presented "encouraging" initial results for a bladder cancer treatment. More news on: Seattle Genetics, Inc., Astellas Pharma Inc., Immunomedics, Inc., Healthca...
BOTHELL, Wash. and TOKYO , Sept. 28, 2019 /PRNewswire/ -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced initial results from the phase 1 clinical trial EV-103. Forty-f...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc. ADR Company Name:
ALPMY Stock Symbol:
OTCMKTS Market:
Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer PR Newswire - If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted...
Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer PR Newswire - If approved, enfortumab vedotin in combination with pembrolizumab ...
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy PR Newswire - Collaborative Research on Innovative Cartilage Organoid Cell Therapy for In...